Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
Vandetanib (ZD6474) is an orally bioavailable small molecule tyrosine kinase inhibitor of multiple growth factor receptors, including RET (Rearrange during transfection), vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR).The activity against RET and VEGF made it a good choice in the here treatment o